In the United States, IL-6R inhibitors have continued to help PMR patients get off steroids. Hopefully more use and more options mean that, in the future, PMR patients get no more steroids than PsA or RA patients #EULAR2025 POS0948 @RheumNow https://t.co/JT7gFDC5rl

• https://x.com/drdavidliew/status/1933513969245041109/photo/1

The new (provisional) 2025 EULAR/ACR classification criteria for anti-synthetase syndrome #EULAR2025 @RheumNow https://t.co/X6VjcN8XZe

• https://x.com/drdavidliew/status/1933792369964433425/photo/1
• https://x.com/drdavidliew/status/1933792369964433425/photo/1
• https://x.com/drdavidliew/status/1933792369964433425/photo/1

@RheumNow EULAR haemochromatosis arthropathy classification criteria Patrick Kiely: please photograph this and take it back to your communities Patient association lead comes to the microphone, and thanks them for making be seen. 🥲 #EULAR2025 @RheumNow https://t.co/9bqdV0fuPk

• https://x.com/drdavidliew/status/1933797947738558480/photo/1

Management of SLE: -Treat early to prevent organ damage -Taper GC to <5mg/d in the first 6m when feasible -New therapies are promising but still unmet needs in LN, limited global access and lacking data in pregnancy. #EULAR2025 @RheumNow https://t.co/UKK8sTYJD2

• https://x.com/AdelaCastro222/status/1932350268102091208/photo/1
• https://x.com/AdelaCastro222/status/1932350268102091208/photo/1

-Difficult to treat RA is a heterogeneous concept -Risk fx: younger onset, high disease activity,erosive disease, comorbidities, depression. -Study in a Spanish cohort with D2T 2/2 inefficacy showed Rituximab, JAKis, and IL-6i had longer survival (hence better tx options). -The https://t.co/ZCZcX9FRfb

• https://x.com/AdelaCastro222/status/1932392453698388399/photo/1

Impact of TNFi on efficacy of Vunakizumab in AS. -Post hoc analysis of Vunakizumab (humanized monoclonal IgG1/k antibody targeting IL-17A) trial on AS pts. -440 total pts, 163 had prior TNFi exposure - At week 16, no significant differences in ASAS20 b/w TNFi exposed pts https://t.co/O9PFOuLa5l

• https://x.com/AdelaCastro222/status/1933460354933141729/photo/1

#EULAR2025 Abstr#OP0041 FcRn-inhibition is showing consistency in #Sjogren. Last year it was Nipocalimab. This proof-of-concept study showed efgartigimod met its primary endpoint, the CRESS response. No difference in ESSPRI. Phase 3 UNITY is underway @RheumNow https://t.co/jw1i4FqkIh

• https://x.com/Yuz6Yusof/status/1932933881730072742/photo/1

#EULAR2025 Abstr#OP0035 SGLT2-i and GLP-1 agonist are increasingly used to treat diabetes. Population based study in Canada showed no significant difference in risk of developing an autoimmune rheumatic disease with GLP-1-RA or SGLT2i relative to DPP4i treatment @RheumNow https://t.co/CvPcOqehtl

• https://x.com/Yuz6Yusof/status/1932939395834818772/photo/1

#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687

• https://x.com/Yuz6Yusof/status/1933397540470182033/photo/1

#EULAR2025 Abstr#OP0265 Do we have convenient biomarkers to help predict new ANA+ referral who would progress to #SLE #Sjogren at 12 mths? Proteomics analysis identified IFN and B-cell markers. Validation is needed and to incorporate clinical items into prognostic model @RheumNow https://t.co/TWClLTKQ0b

• https://x.com/Yuz6Yusof/status/1933460933751238740/photo/1

#EULAR2025 Abstr#POS0318 Single timepoint assessment may not show true picture of #SLE control. Data from BILAG-BR registry using machine learning showed 6 trajectories with clinical meaning: -Nonresponse with high activity: dsDNA-ve & RNP+ -Response-flare: active MSK @RheumNow https://t.co/VrI8e4ONtM

• https://x.com/Yuz6Yusof/status/1933489456524206157/photo/1

#WIN in systemic sclerosis (SSc): -Ongoing trials now targeting multiple pathways. -CONQUEST platform may reshape research in Ssc and other autoimmune diseases. -Revised CRISS could replace single organ endpoints for approval. #EULAR2025 @RheumNow https://t.co/kxSeFb5lAU

• https://x.com/AdelaCastro222/status/1933872420135289278/photo/1
• https://x.com/AdelaCastro222/status/1933872420135289278/photo/1
• https://x.com/AdelaCastro222/status/1933872420135289278/photo/1

+RCT in #pSjD #Sjogrens #Disease #Leflunomide + #hydroxychloroquine Vs #PBO 2nd study to show this - same group need to know ▶️what pt to use this in ▶️is there diff organ improvements ⬆️#ESSDAI ⬇️RF ⬇️Ig’s Easy to prescribe ?early, mild dx #EULAR2025 @RheumNow @eular_org https://t.co/JE0VyFRXc6

• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1

#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow

In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ0.008, NS) while lowering biologic costs (Δ€–1,979 [95%CI –3,798;–161]) & total hospital costs (Δ€–1,936 [95%CI –3,753;–119]) over 18mo. Supports https://t.co/CJUpfU2oRA

• https://x.com/synovialjoints/status/1933900613902893138/photo/1